We are live on ! Find out more
SER icon

Serina Therapeutics

32 hedge funds and large institutions have $4.24M invested in Serina Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more capital invested

Capital invested by funds: $3.15M → $4.24M (+$1.08M)

0% more funds holding

Funds holding: 3232 (0)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0% less ownership

Funds ownership: 0.36%0.36% (-0%)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

64% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 11

Holders
32
Holders Change
Holders Change %
0%
% of All Funds
0.5%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
2
Increased
4
Reduced
11
Closed
2
Calls
Puts
Net Calls
Net Calls Change

SER Hedge Fund Activity: Q2 2023 in Review

32 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q2 2023, worth a combined $4.24M — up 34% from $3.15M a quarter earlier.

Fund positioning in SER was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 11 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $7.94K. The largest seller was Bridgeway Capital Management, cutting an estimated $15.2K.

  • 32 institutional investors held Serina Therapeutics (SER) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $4.24M of Serina Therapeutics stock for Q2 2023, up 34% quarter-over-quarter.
  • 2 funds opened new Serina Therapeutics positions in Q2 2023 and 2 closed out, a net change of 0 holders.
  • The largest Serina Therapeutics buyer in Q2 2023 was Susquehanna International Group, an estimated $7.94K added.
  • The largest Serina Therapeutics seller in Q2 2023 was Bridgeway Capital Management, an estimated $15.2K sold.

Based on aggregated 13F filings for Q2 2023.